The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
Expected to open later this year, the facility will significantly increase distribution capacity to meet the growing demand for production materials by Ireland's biopharma industry
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Subscribe To Our Newsletter & Stay Updated
